Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance
- PMID: 18299462
- DOI: 10.1530/EJE-07-0697
Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance
Abstract
Introduction: Acromegaly, a chronic disease caused by GH/IGF-I excess, has a major impact on quality of life (QoL).
Objective: To evaluate QoL of acromegalic patients in relation to control status of the disease.
Design and methods: Single center observational study including 93 patients with acromegaly recruited to complete QoL questionnaire (AcroQol). QoL was evaluated at least 3 months after surgery and/or medical treatment. Patients were divided into two groups: controlled (I) and uncontrolled (II) according to the latest consensus acromegaly 'control' criteria and further subdivided into four subgroups according to the previous pituitary adenoma surgery (Ib and IIb) or without surgery (Ia and IIa).
Results: Mean GH (0.81+/-0.47 ng/ml) and IGF-I (195+/-71 ng/ml) values in group I were significantly lower than in group II (GH, 7.01+/-12.05 ng/ml and IGF-I, 513+/-316 ng/ml; P<0.001). There was no difference in total AcroQol score, physical, or psychological scales between groups I and II. However, when adjusted to age and disease duration since diagnosis, patients of group I (63+/-20%) showed an improved psychological subscale appearance than those of group II (58+/-17%; P=0.035). In group II, IGF-I level was lower after surgery (IIa=588+/-353, IIb=410+/-225 ng/ml; P<0.038), and psychological subscale appearance was significantly better in subgroup IIb (64.9+/-18.1%) than in subgroup IIa who had medical treatment (53.9+/-14.3%; P=0.009).
Conclusion: QoL is severely impaired in acromegalic patients. Control of GH/IGF-I excess by surgery or medical treatment seems to have a positive impact on psychological subscale appearance.
Similar articles
-
Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea.BMJ Open. 2015 Jun 10;5(6):e006898. doi: 10.1136/bmjopen-2014-006898. BMJ Open. 2015. PMID: 26063564 Free PMC article.
-
Octreotide as primary therapy for acromegaly.J Clin Endocrinol Metab. 1998 Sep;83(9):3034-40. doi: 10.1210/jcem.83.9.5109. J Clin Endocrinol Metab. 1998. PMID: 9745397 Clinical Trial.
-
Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study.Eur J Endocrinol. 2006 Aug;155(2):269-77. doi: 10.1530/eje.1.02214. Eur J Endocrinol. 2006. PMID: 16868140
-
Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.J Neurosurg. 2013 Dec;119(6):1467-77. doi: 10.3171/2013.8.JNS13224. Epub 2013 Sep 27. J Neurosurg. 2013. PMID: 24074496 Review.
-
Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature.Endocr Relat Cancer. 2003 Dec;10(4):611-9. doi: 10.1677/erc.0.0100611. Endocr Relat Cancer. 2003. PMID: 14713271 Review.
Cited by
-
Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea.BMJ Open. 2015 Jun 10;5(6):e006898. doi: 10.1136/bmjopen-2014-006898. BMJ Open. 2015. PMID: 26063564 Free PMC article.
-
Clinical, quality of life, and economic value of acromegaly disease control.Pituitary. 2011 Sep;14(3):284-94. doi: 10.1007/s11102-011-0310-7. Pituitary. 2011. PMID: 21597975 Free PMC article. Review.
-
Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly.Pituitary. 2017 Dec;20(6):692-701. doi: 10.1007/s11102-017-0835-5. Pituitary. 2017. PMID: 28887782 Free PMC article.
-
Medical therapy of acromegaly.Int J Endocrinol. 2012;2012:268957. doi: 10.1155/2012/268957. Epub 2012 Apr 10. Int J Endocrinol. 2012. PMID: 22550484 Free PMC article.
-
Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.Biologics. 2008 Sep;2(3):463-79. doi: 10.2147/btt.s3356. Biologics. 2008. PMID: 19707377 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources